Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country healthier and stronger."

As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, Medicare director Meena Seshamani, and FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni have retired or intend to retire prior to Trump's inauguration on Jan. 20.

In a wide-ranging interview, Xavier Becerra, President Biden’s health secretary, defended his tenure and hinted that he might run for governor of California.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

Changes may be on the horizon regarding the cost of diabetes and weight loss drug titans like Ozempic and Wegovy. The Biden administration has announced the next round of prescription drugs selected for Medicare price negotiations.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manuf

Among the dozens of Biden-era executive orders he rescinded on day one, President Trump nixed one that aimed to explore new health care payment models that would lower prescription costs for Medicare and Medicaid beneficiaries.

Among the dozens of Biden-era executive orders he rescinded on day one, President Trump nixed one that aimed to explore new health care payment models that would lower prescription costs for Medicare and Medicaid beneficiaries.

The Biden Administration announced the next batch of 15 prescription drugs that will be included in price negotiations with companies — with the aim of lowering costs for people covered by Medicare.